Vaccines against strains originating from avian flu may achieve poor yields in egg-based systems. Consequently, both public and private interest in alternative systems is high.
Amanda Shipman
Advertisement
Articles by Amanda Shipman
Advertisement
Latest Updated Articles
Cell-Culture–Based Manufacturing: Meeting the Challenge of 21st Century InfluenzaPublished: August 2nd 2007 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
